Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
SpringWorks Therapeutics Inc (SpringWorks Therapeutics) is a commercial-stage biopharmaceutical company that develops and delivers precision medicine for cancer treatment. It carries out researching and developing targeted oncology therapies. The company's pipeline products include nirogacestat, mirdametinib, and SW-682. SpringWorks Therapeutics' products are primarily used by patients with rare tumors, hematological cancers, and biomarker-defined metastatic solid tumors. The company operates across the US. SpringWorks is headquartered in Stamford, Connecticut, the US.
Headquarters
United States of America
Address
100 Washington Blvd, Stamford, Connecticut, 06902-9302
Website
www.springworkstx.com
Telephone
1 203 8839490
No of Employees
368
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$191.6M
SpringWorks Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Nirogacestat: |
| Adult desmoid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In July, the company was acquired by Merck KGaA, a science and technology company. |
| 2025 | Contracts/Agreements | In February, the company partnered with Jennifer Fisher to accelerate understanding of desmoid tumors. |
| 2025 | Regulatory Approval | In February, the company received approval from the U.S. Food and Drug Administration for GOMEKLI (mirdametinib), SpringWorks’ MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas not amenable to complete resection. |
Competitor Comparison
| Key Parameters | SpringWorks Therapeutics Inc | Tonix Pharmaceuticals Holding Corp | Azevan Pharmaceuticals Inc | BetaCat Pharmaceuticals Inc | BioXcel Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Stamford | Chatham | Bethlehem | Houston | Branford |
| State/Province | Connecticut | New Jersey | Pennsylvania | Texas | Connecticut |
| No. of Employees | 368 | 81 | - | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel S. Lynch | Chairman | Executive Board | 2019 | 66 |
| Saqib Islam | Director; Chief Executive Officer | Executive Board | 2018 | 55 |
| Francis I. Perier | Chief Financial Officer | Senior Management | 2019 | 65 |
| Kristin Patterson, Ph.D. | Chief Technology Officer; Chief Operating Officer | Senior Management | - | - |
| Badreddin Edris, Ph.D. | Chief Operating Officer | Senior Management | 2018 | 38 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer